A review of osteoporosis management in younger premenopausal women

被引:1
作者
McLendon, Amber N. [1 ,2 ]
Woodis, C. Brock [3 ,4 ]
机构
[1] Campbell Univ, Coll Pharm & Hlth Sci, POB 1090, Buies Creek, NC 27511 USA
[2] Glenaire Inc, Buies Creek, NC 27511 USA
[3] Campbell Univ, Coll Pharm & Hlth Sci, Buies Creek, NC 27511 USA
[4] Duke Family Med, Buies Creek, NC 27511 USA
关键词
bisphosphonates; bone loss; female; hormone therapy; osteoporosis; premenopausal; teriparatide; treatment; vitamin D; young;
D O I
10.2217/WHE.13.73
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The purpose of this review is to describe the available evidence for osteoporosis treatments in young and premenopausal women. A review of articles evaluating the treatment or prevention of osteoporosis in young (age less than 50 years) or premenopausal women was conducted. Several trials evaluating the treatment of anorexia nervosa and use of hormone therapy in those women, the use of bisphosphonates in women undergoing chemotherapy for breast cancer and the use of bisphosphonates, teriparatide and vitamin D in women with glucocorticoid-induced osteoporosis are described. Limited data were found to support the treatment of osteoporosis in women with idiopathic osteoporosis or cystic fibrosis, or after kidney transplant. The evidence for treatment of osteoporosis in premenopausal women is not nearly as robust as that for postmenopausal osteoporosis. Although fracture risk in the premenopausal population is low, women with secondary osteoporosis may benefit from treatment with various agents, depending upon the condition.
引用
收藏
页码:59 / 77
页数:19
相关论文
共 63 条
[1]  
Actonel, 2013, ACT
[2]   Efficacy of alendronate in adults with cystic fibrosis with low bone density [J].
Aris, RM ;
Lester, GE ;
Caminiti, M ;
Blackwood, AD ;
Hensler, M ;
Lark, RK ;
Hecker, TM ;
Renner, JB ;
Guillen, U ;
Brown, SA ;
Neuringer, IP ;
Chalermskulrat, W ;
Ontjes, DA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (01) :77-82
[3]   Natural history of bone loss over 6 years among premenopausal and early postmenopausal women [J].
Bainbridge, KE ;
Sowers, MF ;
Crutchfield, M ;
Lin, X ;
Jannausch, M ;
Harlow, SD .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 156 (05) :410-417
[4]   Management of osteoporosis in a pre-menopausal woman [J].
Bhalla, Ashok K. .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2010, 24 (03) :313-327
[5]   Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club [J].
Body, J. J. ;
Bergmann, P. ;
Boonen, S. ;
Boutsen, Y. ;
Devogelaer, J. P. ;
Goemaere, S. ;
Reginster, J. Y. ;
Rozenberg, S. ;
Kaufman, J. M. .
OSTEOPOROSIS INTERNATIONAL, 2007, 18 (11) :1439-1450
[6]   Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: A report of four cases [J].
Chan, Brendan ;
Zacharin, Margaret .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06) :2017-2020
[7]   Clinical Characteristics and Medication Use among Premenopausal Women with Osteoporosis and Low BMD: The Experience of an Osteoporosis Referral Center [J].
Cohen, Adi ;
Fleischer, Jessica ;
Freeby, Matthew J. ;
McMahon, Donald J. ;
Irani, Dinaz ;
Shane, Elizabeth .
JOURNAL OF WOMENS HEALTH, 2009, 18 (01) :79-84
[8]   Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis [J].
de Nijs, Ron N. J. ;
Jacobs, Johannes W. G. ;
Lems, Willem F. ;
Laan, Roland F. J. ;
Algra, Ale ;
Huisman, Anne-Margriet ;
Buskens, Erik ;
de laet, Chris E. D. ;
Oostveen, Ans C. M. ;
Geusens, Piet P. M. M. ;
Bruyn, George A. W. ;
Dijkmans, Ben A. C. ;
Bijlsma, Johannes W. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (07) :675-684
[9]   Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study [J].
Delmas, PD ;
Balena, R ;
Confravreux, E ;
Hardouin, C ;
Hardy, P ;
Bremond, A .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :955-962
[10]  
Dornemann TM, 1997, J SPORT MED PHYS FIT, V37, P246